Patient Access To Regenerative Health
It's A Door We Can Open Together.
Our Mission
“Our mission is to support and strengthen patient access to safe, timely, and effective regenerative medicine technology and treatments."
Who We Are
The Regenerative Outcomes Foundation was established by Doug Oliver, a Nashville, TN, resident who was legally blind from macular degeneration, and who, through adult stem-cell treatment, had his sight restored. Coming on the heels of Oliver’s work on the 21st Century Cures Act, which passed Congress with impressive bipartisan support and was signed into law in December 2016, the foundation’s primary objective is to help improve access to these cutting-edge regenerative medicine procedures and treatments by working both with patients seeking safe and effective help and the innovative providers and companies able to meet their medical needs.
​
OUR FOUNDER
Doug Oliver, MSW, is a patient ambassador, healthcare consultant, and writer in Nashville, Tennessee.
He graduated Cum Laude with a Master’s Degree in Social Work from University of New England, and has an extensive career in medical social work, health care regulatory compliance consulting, gerontology, and therapeutic case advocacy.
​
BOARD OF DIRECTORS
We invite you to meet our Board of Directors, powered by dedicated members who share a passion for advancing access to regenerative medicine. We apply our professional expertise in medicine, translational sciences, business, accounting, public policy and patient advocacy to accomplish the Foundation's mission and goals
What We Do
The Regenerative Outcomes Foundation is a 501(c)3 tax-exempt charitable organization that serves both patients seeking healing through regenerative medicine and the researchers seeking to develop it.
Our current initiatives include:
​
-
Developing patient counseling protocols. There is much that providers and patients alike have yet to understand regarding the complex emotional, behavioral, social, and spiritual factors that impact patient outcomes, functioning, and quality of life. The Foundation collaborates with private and public sector stakeholders to help discover answers through specialized projects and support for clinical trials that consider quality of life and emotional well-being.
​
-
Advocacy and awareness. Patient engagement, specialized social media groups, provider compliance education, support, and elevating the patient position in direct drug development activities are all urgent patient needs, and reform in messaging and communicating hope to patients becomes central to meeting them. We participate in community events and conferences, and empower patients to get involved using their personal narratives to inspire and guide industry stakeholders.
​
-
Promoting just regulatory policies. Promoting social and health policy efforts that will maximum patient access, self-determination, the right to information, affordability, and fair distribution of research funding supporting regenerative medicine are all critical to creating a national response to technologies with tremendous healing potential. Consistent with its social justice roots, The Regenerative Outcomes Foundation leverages its respected position within the policymaker community to call for equity in policy that emphasizes timely and flexible delivery of healing opportunities for all.
​
-
Advancing robust regenerative medicine data collection.​ As part of a nationwide coalition of key thought leaders and influencers, the Foundation is active in raising awareness, providing advisory support, advocating for, and actively pursuing social policy change to bring a commitment to clinical trials and real-world evidence to current practitioners researching cellular medicine in the context of their practice. Information is power, and proper use of data informs regulators to help make decisions on the need for clinical trials for a diverse patient population. We focus on helping all stakeholders lean into regulatory compliance and build evidenced-based data to support safe drug development and rapid access.